Related Experiment Video

Updated: Jun 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Utility of adjuvant systemic therapy in melanoma

A M M Eggermont1, A Testori, J Marsden

  • 1Department of Surgical Oncology, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|July 21, 2009
PubMed

Insights

Interferon (IFN) therapy offers a modest benefit in disease-free survival for melanoma patients but shows limited impact on overall survival. Further research is needed to identify patients who may benefit from this adjuvant treatment.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Stage IV melanoma lacks effective treatments, impacting adjuvant therapies for earlier stages (II/III).
  • Current adjuvant therapies like chemotherapy, immunostimulants, and vaccines show minimal success in melanoma.
  • Interferon (IFN) has demonstrated effects on relapse-free survival (RFS) but not significantly on overall survival (OS).

Purpose of the Study:

  • To evaluate the effectiveness of adjuvant Interferon (IFN) therapy in melanoma.
  • To analyze the impact of IFN on disease-free survival (DFS) and overall survival (OS).
  • To explore regional variations and optimal dosing strategies for IFN in melanoma treatment.

Main Methods:

  • Review of clinical trials and meta-analyses on adjuvant Interferon (IFN) therapy for melanoma.
  • Comparison of IFN-treated patients with observation-only control groups.
  • Analysis of treatment duration, dosage, and regional prescribing practices in Europe.

Main Results:

  • Meta-analysis showed a 7% prolongation in disease-free survival (DFS) and a 3% benefit in overall survival (OS) with IFN therapy.
  • No clear differences in efficacy were observed based on IFN dose or treatment duration.
  • Significant regional variations in IFN use exist, with common low-dose prescription in Central/Mediterranean Europe and infrequent use in Northwest Europe.

Conclusions:

  • Adjuvant Interferon (IFN) therapy provides a marginal survival benefit for some melanoma patients.
  • Observation remains a valid control arm in adjuvant melanoma clinical trials.
  • Further research is required to identify predictive biomarkers for patient selection and optimize IFN therapy.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...